Medical Marijuana Pages

OCTOBER 9, 2024

DEA Potential Reclassification of Marijuana Policy. In recent discussions surrounding drug policy reform, the reclassification of marijuana by the Drug Enforcement Administration (DEA) has emerged as a pivotal issue. Read More

DEA 122

DEA Policy Marijuana Cannabis 122

Cannabis Law Report

SEPTEMBER 1, 2021

Marijuana Moment reports. In its response, the agency argued that marijuana has no currently accepted medical value. Lawyers for the group appealed that decision, asking the court to order DEA to initiate a formal rulemaking process, which would involve expert testimony and public comment. In a ruling filed on Monday, the U.S.

DEA 109

DEA Marijuana Policy Cannabis 109

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Relevant AAFP Policy. Marijuana Possession for Personal Use. Executive Summary.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Veriheal

DECEMBER 21, 2022

President Joe Biden has officially signed a marijuana research bill into law. 8454, the “Medical Marijuana and Cannabidiol Research Expansion Act,” has been passed. attorney general 60 days to either approve a given application or request supplemental information from the marijuana research applicant. The law gives the U.S.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

Connor & Connor PLLC

AUGUST 15, 2024

On October 6 th , 2022, President Joe Biden asked the Secretary of the Department of Health and Human Services (HHS) and the Attorney General to review how marijuana is classified. Marijuana was put on the Schedule I list by Congress when they enacted the CSA (Controlled Substances Act).

Marijuana 52

Marijuana DEA Policy Business 52

Veriheal

JANUARY 24, 2025

A Schedule I drug is described as having a high potential for abuse and/or addiction with no accepted medical use as treatment. A transition into a Schedule III would mean that cannabis would then be defined as having moderate potential for abuse but with accepted medical use within federal law. In September 2023, the U.S.

DEA 98

DEA Policy Cannabis Law 98

Veriheal

NOVEMBER 7, 2024

Department of Justice (DOJ) put forth a proposal to reclassify “marijuana” (the legal term for cannabis plants and their products with over 0.3% The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge.

DEA 97

DEA Policy Chronic Pain Marijuana 97